Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings Of The Fortnight: Recent IPO Slowdown Not Necessarily A Harbinger For A Bad 2014

This article was originally published in The Pink Sheet Daily

Executive Summary

Series A financing volume is up in recent years, suggesting that 2014 will be a strong year for biotechs opting to go public. Plus financing news from Atara Biotherapeutics, Crescendo Biologics, Acucela and TetraLogic.


Related Content

Biotech IPO Candidates Ramp Up To Get Out Before The Holidays
Start-Ups, With An Eye On Success In Wet AMD, Tackle The Dry Form


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts